In partnership with
The Bottom Line Upfront 💡
GoodRx $GDRX ( ▲ 0.8% ) is a profitable prescription price comparison platform trading at roughly half its intrinsic value despite declining user metrics and competitive threats. While the business faces headwinds from retail pharmacy consolidation and potential Big Tech competition, strong cash generation and improving margins make it an attractive value play for patient investors.
Sponsorship
Turn AI into Your Income Engine
Ready to transform artificial intelligence from a buzzword into your personal revenue generator?
HubSpot’s groundbreaking guide "200+ AI-Powered Income Ideas" is your gateway to financial innovation in the digital age.
Inside you'll discover:
A curated collection of 200+ profitable opportunities spanning content creation, e-commerce, gaming, and emerging digital markets—each vetted for real-world potential
Step-by-step implementation guides designed for beginners, making AI accessible regardless of your technical background
Cutting-edge strategies aligned with current market trends, ensuring your ventures stay ahead of the curve
Download your guide today and unlock a future where artificial intelligence powers your success. Your next income stream is waiting.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Think of GoodRx as the "Kayak for prescription drugs" - but instead of finding cheap flights, they help Americans find affordable medications. Founded in 2011 by Trevor Bezdek and Douglas Hirsch, the company emerged from a simple but infuriating realization: the same prescription can cost wildly different amounts at different pharmacies, and most people have no clue about this.
Here's how the magic works: GoodRx operates a massive data-crunching machine that processes over 420 billion pricing data points daily (yes, billion with a B 🤯). They aggregate prescription prices from pharmacy benefit managers (PBMs), retail pharmacies, and pharmaceutical manufacturers, then present this information through a consumer-friendly app and website. When you find the lowest price, you save a "GoodRx code" to your phone and present it at the pharmacy - boom, instant savings.
The money-making machine has three main engines:
Prescription Transactions (68% of revenue): When someone uses a GoodRx code, the company gets paid by the PBM or pharmacy - either a percentage of the transaction or a fixed fee. The beautiful part? Once you use a code at a pharmacy, it stays in their system, so GoodRx keeps earning on your refills without you having to do anything.
Pharma Direct (19% of revenue, growing 41% ↗️): Pharmaceutical companies pay GoodRx to advertise their drugs and integrate their discount programs. Think of it as sponsored content, but for medications you actually need.
Subscriptions (11% of revenue): GoodRx Gold and other premium services offer even deeper discounts for a monthly/annual fee, plus perks like telehealth visits and prescription delivery.
Key metrics they obsess over: Monthly Active Consumers (currently 5.3M, unfortunately trending down ↘️), subscription plans (674K), and something called "repeat activity" - basically how often people come back to use their service.
The company employs 697 people (all full-time) from their Santa Monica headquarters, serving a market they estimate at $600-710 billion. Not too shabby for a prescription price comparison tool! 💰
Key Takeaway: GoodRx is essentially a middleman that makes prescription pricing transparent while taking a cut from the savings they generate - a win-win that works until it doesn't.
Layer 2: Category Position 🏆
GoodRx sits pretty at the top of the prescription price comparison food chain, claiming to be "the largest healthcare-focused internet platform for prescription prices and discounts." But here's where things get interesting (and a bit concerning).
The competitive landscape is weird: Instead of facing off against similar startups, GoodRx's biggest threats come from massive e-commerce companies that could theoretically crush them with superior resources and existing customer relationships. Think Amazon deciding to get serious about prescription pricing - that would be a "code red" moment for GoodRx.
Their secret sauce includes:
Brand recognition and word-of-mouth (your pharmacist probably knows about GoodRx)
Scale advantages in data aggregation (those 420 billion daily data points don't collect themselves)
Proprietary technology for combining prices from multiple sources (they actually have patents on this)
Network effects: more consumers → better pricing → more consumers
But here's the plot twist: GoodRx's biggest barrier isn't competition - it's consumer ignorance. Many Americans simply don't know that prescription prices vary wildly between pharmacies or that cash prices can beat insurance copays. This creates a massive opportunity but also means the company has to spend heavily on education and marketing (41.6% of revenue goes to sales & marketing 📢).
Recent challenges are real: The Rite Aid bankruptcy in May 2025 and Walgreens store closures have created headwinds. When pharmacies disappear, so do GoodRx's revenue opportunities. Plus, one of their "integrated savings programs" saw a material volume reduction in 2025, contributing to an estimated $35-40M revenue hit.
The government is getting involved: The launch of TrumpRx.gov in February 2026 (yes, that's a real thing) represents both opportunity and threat. GoodRx is a "key integration partner," but government-sponsored competition is never ideal for private companies.
Key Takeaway: GoodRx dominates a niche market but faces existential threats from both tech giants and government initiatives - classic "big fish in a small pond" syndrome.
Layer 3: Show Me The Money! 📈
Let's dive into the financial nitty-gritty, because this is where GoodRx's story gets both impressive and concerning.
Revenue Breakdown (2025):
Prescription Transactions: $544M (68%, down 6% ↘️) - The bread and butter, but it's getting stale
Pharma Direct: $151M (19%, up 41% ↗️) - The growth star, pharmaceutical companies paying for access
Subscriptions: $84M (11%, down 3% ↘️) - Steady but not spectacular
Other: $18M (2%, down 16% ↘️) - Telehealth and miscellaneous services
The good news: Total revenue was essentially flat at $797M (up a measly 0.6%), but the company dramatically improved profitability. Operating margin jumped from 8.3% to 11.0% ↗️, and net income more than doubled from $16M to $30M. That's some serious operational discipline! 💪
The concerning news: Monthly Active Consumers dropped 19.7% year-over-year ↘️, falling from 6.6M to 5.3M. When your core user base is shrinking, that's not exactly a recipe for long-term growth.
Cost structure tells a story:
Sales & Marketing: 41.6% of revenue (down from 46.3%) - Still massive but improving
Product Development: 15.2% of revenue - Reasonable for a tech company
General & Administrative: 14.3% of revenue - Corporate overhead
Cost of Revenue: 7.2% of revenue - Impressively low, showing the beauty of their asset-light model
Cash flow is king: The company generated $168M in operating cash flow and $164M in free cash flow, representing a healthy 20.6% free cash flow margin. They're not just profitable on paper - they're generating real cash.
Capital allocation strategy: GoodRx has been aggressive with share buybacks, repurchasing $217M worth of stock in 2025 (including $85M from related parties at a discount - nice deal if you can get it). They also made two acquisitions totaling $43M to expand their capabilities.
Debt situation: The company carries $488M in net debt with an 8.55% effective interest rate. Not terrible, but not great either in a rising rate environment.
Key Takeaway: GoodRx is a cash-generating machine with improving margins, but declining user metrics suggest the growth story is getting more complicated.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Significantly Undervalued 🎯
Key assumptions driving the valuation:
Revenue growth moderates to 2-4% annually (reflecting market maturity)
Operating margins gradually improve to 13.5% by 2030 (operational efficiency gains)
Terminal growth rate of 2.5-3.5% (conservative given healthcare market dynamics)
The math is compelling: Even in the conservative scenario, GDRX appears to be trading at roughly half its intrinsic value. The company's strong free cash flow generation ($164M in 2025) and improving margins support a higher valuation, especially considering their market-leading position.
Recommendation: GDRX looks like a classic "cigar butt" investment - not the prettiest business, but trading at a significant discount to intrinsic value with decent cash generation.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
The prescription affordability problem gets worse, not better: As insurance copays rise and government programs shift costs to consumers, GoodRx becomes more essential, not less
Pharma Direct becomes the growth engine: The 41% growth in this segment continues as pharmaceutical companies increasingly need direct-to-consumer channels
Operational leverage kicks in: The company's high fixed costs become an advantage as they achieve scale, driving margins toward 15%+
Bear Case 🐻
Big Tech decides to play: Amazon, Google, or Apple could launch competing services with superior resources and existing customer relationships
Government competition intensifies: TrumpRx.gov and similar initiatives could commoditize prescription pricing, reducing GoodRx's value proposition
The retail pharmacy apocalypse continues: More Rite Aid-style bankruptcies and closures shrink the addressable market faster than GoodRx can adapt
The Bottom Line: GoodRx is a profitable, cash-generating business trading at a significant discount to intrinsic value, but it operates in a market with powerful forces working against it. The company has survived and thrived for over a decade, suggesting some durability, but the next few years will test whether they can navigate an increasingly challenging landscape. For value investors willing to bet on management's ability to adapt, the risk-reward looks attractive at current prices.
What to Watch 👀
Monthly Active Consumer trends: If this metric continues declining below 5M, it signals fundamental problems with the business model. Watch for stabilization or, better yet, growth.
Pharma Direct revenue growth: This is the bright spot - if growth slows below 20% annually, question whether the diversification strategy is working.
Retail pharmacy consolidation: Keep an eye on major pharmacy chains' financial health. More bankruptcies = more headwinds for GoodRx.
TrumpRx.gov adoption: Monitor how much market share this government platform captures and whether it truly competes with or complements GoodRx's offerings.
Operating margin expansion: Watch for continued improvement toward 13-15%. If margins plateau around current levels, the operational leverage thesis breaks down.
Debt refinancing: With $488M in debt maturing in 2029, keep an eye on refinancing terms and interest rate impacts on cash flow.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.